Cuộc họp công bố kết quả kinh doanh quý 2/2026 của Co-Diagnostics (CODX): Tiến trình nộp hồ sơ lên FDA có tiến triển khi lượng tiền mặt sụt giảm
Doanh thu Quý 2/2026 của Co-Diagnostics đạt 166.000 USD trong bối cảnh khoản lỗ được thu hẹp, đồng thời CODX đã nộp hồ sơ xét nghiệm cúm và RSV lên FDA và kết thúc kỳ với 3,6 triệu USD tiền mặt.
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.